The First line systemic chemotherapy in metastatic gastric carcinoma: A comparison of Docetaxel, Cisplatin and Fluorouracil (DCF) versus Cisplatin and Fluorouracil (Cf); versus Epirubicin, Cisplatin and Fluorouracil (ECF) regimens in clinical setting

Hepato-Gastroenterology

Volumn 58, Issue 105, 2011, Pages 208-212

  Kilickap, Saadettin ^a   Yalcin, Suayib ^a   Ates, Ozturk ^a   Tekuzman, Gulten ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Gastric cancer

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MEPREDNISONE; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVARY METASTASIS; PERITONEUM CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORIMOTOR NEUROPATHY; SEPSIS; SOFT TISSUE METASTASIS; STOMACH ADENOCARCINOMA; STOMATITIS; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; STATISTICS, NONPARAMETRIC; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 79955039234     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Roder DM. The epidemiology of gastric cancer. Gastric Cancer 2002; 5 Suppl 1: 5-11
2. Yalcin S. Gastric Cancer in Turkey. Gastrointestinal Cancer Research 2009;61:900-2
3. Glimelius B, Ekstrom K, Hoffman K, et al. Rand omized comparison between chemotherapy plus best sup portive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168 (Pubitemid 27112884)
4. Pyrhönen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 58-91
5. Roth AD, Fazio N, Stupp R, et al. Docetaxel, cispla tin, and fluorouracil; docetaxel and cisplatin; epirubicin, cisplatin, and fluorourasil as systemic treatment for ad vanced gastric carcinoma: A randomized phase II trial of the Swiss Group for clinical cancer research. J Clin Oncol 2007; 25(22): 3217-3223 (Pubitemid 47325604)
6. Rivera F, Vega-Villegas ME, Lopez-Brea MF. Chemotherapy of advanced gastric cancer. Cancer Treat Rev 2007; 33(4): 325-324
7. Kim NK, Park YS, Heo DS, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71(12): 3813-3818.
8. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21(1): 54-59.
9. Webb A, Cunningham D, Scarffe JH, et al. Rand omized trial comparing epirubicin, cisplatin, and fluorou racil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15(1): 261-267 (Pubitemid 27020582)
10. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19(8): 1450-1457
11. Bang YJ, Kang WK, Rang YK, et al. Docetaxel 75 mg/ m2 is active and well tolerated in patients with metastat ic or recurrent gastric cancer: A phase II trial. Jpn J Clin Oncol 2002; 32: 248-254 (Pubitemid 43102808)
12. Ridwelski K, Gebauer T, Fahlke J, et al. Combina tion chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001; 12: 47-51 (Pubitemid 32162447)
13. Constenla M, Garcia-Arroyo R, Lorenzo I, et al. Do cetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: Results of a phase II study. Gas tric Cancer 2002; 5: 142-147 (Pubitemid 35238893)
14. Thuss-Patience PC, Kretzschmar A, Repp M, et al. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gas tric adenocarcinoma: a randomized phase II study. J Clin Oncol 2005; 23(3): 494-501 (Pubitemid 46237444)
15. Wagner AD, Grothe W, Haerting J, et al. Chemo therapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24(18): 2903-2909 (Pubitemid 46630593)
16. Fhalke J, Ridwelski K, Schmidt C, et al. A multicen tre phase II study of docetaxel plus cisplatin for the treat ment of advanced gastric carcinoma. Chemotherapy 2007; 53: 454-460 (Pubitemid 350089884)
17. Cutsem E, Moisyenko VM, Tjuladin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil com pared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group. J Clin Oncol 2006; 24: 4991-4997 (Pubitemid 46631401)
18. Sadighi S, Mohagheghi MA, Montazeri A, Sadighi Z. Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF). BMC Cancer 2006; 6: 274-279
19. Yalcin S. The Increasing Role of Pharmacogenetics in the Treatment of Gastrointestinal Cancers Gastrointest Cancer Res. 2009; 3:197-203.